Stocksrunner Posted - 21 minutes ago

The Comeback Kings ruled the charts today! $CLRB $NNOX $LTBR $CAN and $CNTA hit their lows but surged back to close higher! Talk about a royal recovery

BreckHoho Posted - 2 hours ago

MYNZ I don't give a damn about bots, I trust this stock 100000000%. Deal with Thermo Fisher Healthcare Giant is a huge credibility. 1/ German gov stake 10% 2/ Thermo Fisher partnership 3/ Frankie Muniz Malcolm in the Middle support 4/ Petra Starke former WH senior advisor of Obama 5/ 75M patients coverage in EU + 9labs 6/ 88% pre-cancer results unlike competitors EXAS 43% and GH 13%. 7/ RS will be cancelled 🤞extension of 180 days by nasdaq? 8/ 30M shares offering deal, TMO will get that? Wtf are you waiting for ??? Crush this shorties 🔥🚀 $CNTA $TARS

Stocksrunner Posted - 3 days ago

Comeback Kings of the Day! 👑 These stocks hit rock bottom during the session but made a heroic comeback to close higher: $BTDR $IPDN $VVPR $CNTA $SERV

Thestocktraderhubzee Posted - 3 days ago

WATCHLIST NOV 18 2024 $CGTX Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target $VNRX D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target $HQI Barrington Research Maintains Outperform on HireQuest, Raises Price Target to $18 $KYTX Wells Fargo Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $24 $CNTA Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $28

Marco7676 Posted - 5 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $NRIX $CNTA

DonCorleone77 Posted - 1 week ago

$CNTA Centessa reports Q3 EPS (37c), consensus (42c) "The totality of data across our OX2R agonist program continues to reinforce the strength of our discovery engine and the therapeutic potential of these assets across a broad spectrum of disorders," said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. "The Phase 1 interim data for ORX750, now updated to include over 70 subjects dosed with ORX750, continue to support its best-in-class potential in NT1, NT2 and IH. Based on the strength of these interim data, we recently initiated a Phase 2a clinical study of ORX750 in patients with NT1, NT2 and IH. Similar to our Phase 1 study, which enabled a move from IND clearance to clinical data in the course of a few months, we expect our Phase 2a study design to generate clinical data for all three indications in 2025 and enable dose selection for future pivotal studies with the potential to be first-in-class in NT2 and IH."

Thelonius_Stonk Posted - 1 week ago

$CNTA high n tight

Doozio Posted - 1 week ago

$CNTA da FUTUre of 🧠⏰ is NEXT week on eps INTA 🧠⏰♾️

SmartestMoney Posted - 2 weeks ago

$CNTA Yes

insiderbuyingselling Posted - 10/25/24

$CNTA new insider selling: 11742 shares. http://insiderbuyingselling.com/?t=CNTA

insiderbuyingselling Posted - 10/23/24

$CNTA new insider selling: 55000 shares. http://insiderbuyingselling.com/?t=CNTA

insiderbuyingselling Posted - 09/28/24

$CNTA new insider selling: 16619 shares. http://insiderbuyingselling.com/?t=CNTA

DonCorleone77 Posted - 09/26/24

$CNTA Centessa presents preclinical Data for ORX142 in excessive daytime sleepiness Centessa Pharmaceuticals shared new preclinical data from non-human primate - NHP - studies of ORX142, an investigational, novel, orexin receptor 2, or OX2R, agonist being advanced for the treatment of excessive daytime sleepiness - EDS - in select neurological, neurodegenerative and psychiatric disorders. ORX142 is the second drug candidate from the company's growing pipeline of OX2R agonists and is in IND-enabling studies. The preclinical data were featured in a late-breaking poster presentation at the 27th Congress of the European Sleep Research Society in Seville. ORX142 potently activated the human OX2R with an EC50 of 0.069 nM and greater than 13,000-fold selective over the human orexin receptor. Oral administration of ORX142 showed significant activity at the lowest dose tested, which was 0.03 mg/kg. ORX142 induced sustained increases in wakefulness that suppressed NREM and REM sleep at the lowest dose tested. Wakefulness induced by ORX142 was associated with normal physiological arousal and EEG power spectra signatures of enhanced alertness and attention. No significant pharmacological activity was observed in GPCR selectivity and in vitro safety panels.

Stock_Titan Posted - 09/26/24

$CNTA Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) https://www.stocktitan.net/news/CNTA/centessa-pharmaceuticals-presents-preclinical-data-for-orx142-a-bd3rodycttwu.html

intratio Posted - 09/25/24

https://www.intratio.com/stock-forecast/CNTA Centessa Pharmaceuticals plc The AI has detected the value of this stock has bleak prospects for the foreseeable future and is facing significant downsides in the longer term $CNTA

intratio Posted - 09/24/24

$CNTA https://www.intratio.com/stock-forecast/CNTA Centessa Pharmaceuticals plc The artificial intelligence has forecasted that the price of this stock has a poor setup for the immediate future and harbors dim hopes for the future

insiderbuyingselling Posted - 2 months ago

$CNTA new insider selling: 55000 shares. http://insiderbuyingselling.com/?t=CNTA

AnaChart Posted - 2 months ago

$CNTA https://anachart.com/wp-content/uploads/ana_temp/1726851753_soc-img.jpg

Thestocktraderhubzee Posted - 2 months ago

WATCHLIST SEP 20 2024 $AEP Jefferies Initiates Coverage On American Electric Power with Hold Rating, Announces Price Target of $107 $CNTA Morgan Stanley Upgrades Centessa Pharmaceuticals to Overweight, Raises Price Target to $26 $TGT Telsey Advisory Group Maintains Outperform on Target, Maintains $195 Price Target $PGNY Jefferies Maintains Buy on Progyny, Lowers Price Target to $24 $GRMN Tigress Financial Maintains Strong Buy on Garmin, Raises Price Target to $215

DonCorleone77 Posted - 2 months ago

$CNTA Morgan Stanley upgrades Centessa on 'best-in-class' potential of ORX750 Morgan Stanley upgraded Centessa to Overweight from Equal Weight with a price target of $26, up from $11. The firm had been "cautiously optimistic heading" into the Phase 1 readout based on safety signals seen with competing candidates in the space, but it now contends following the recent report of topline ORX750 Phase 1 results in healthy volunteers that the data "remove the largest overhang on the orexin 2 field and confirm it has potential to be best-in-class for treating narcolepsy." The firm updated its model and now includes market models for ORX750 in narcolepsy type 2 and idiopathic hypersomnia, the analyst noted.

basscat12 Posted - 2 months ago

$DASH $PRLD $CNTA Pre-Market Mash-Up, page 4, Highlighted Analyst Activity, courtesy @TheTradeXchange , the Best Squawk On The Street, and presented with @Vegas1 to help prepare for today's market!

AnaChart Posted - 2 months ago

$CNTA https://anachart.com/wp-content/uploads/ana_temp/1726491703_soc-img.jpg

tradingtwenty Posted - 2 months ago

$CNTA has trended 21 times in the past 24 hours (based on 5 minute intervals). Latest press release on Sep 12, 2024 10:34 PM: Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares Link: https://tradingtwenty.com/news/620806/centessa-pharmaceuticals-announces-pricing-of-upsized-225000000-public-offering-of-american-depositary-shares

DonCorleone77 Posted - 2 months ago

$CNTA Centessa 15.25M share Spot Secondary priced at $14.75 The deal size was increased to 15.2M shares from 10.9M and priced below last closing price of $15.10. Goldman Sachs, Leerink, Evercore ISI, Guggenheim and BMO Capital acted as joint book running managers for the offering.

insiderbuyingselling Posted - 2 months ago

$CNTA new insider selling: 30000 shares. http://insiderbuyingselling.com/?t=CNTA

Stock_Titan Posted - 2 months ago

$CNTA Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares https://www.stocktitan.net/news/CNTA/centessa-pharmaceuticals-announces-pricing-of-upsized-225-000-000-nzivvvv3kw2a.html

StockInvest_us Posted - 2 months ago

Signal alert: $CNTA - Overbought Trend Short (Overvalued) https://stockinvest.us/l/qS6ND51Dl4

Stock_Titan Posted - 2 months ago

$CNTA Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares https://www.stocktitan.net/news/CNTA/centessa-pharmaceuticals-announces-150-000-000-proposed-public-65fqu0xjmriq.html

Thestocktraderhubzee Posted - 2 months ago

$CNTA Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $24

30DeltaSpy Posted - 2 months ago

$CNTA $5 billion dollar narcolepsy opportunity